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Background: Soshiho-tang (SH; Chinese name, Xiao-Chai-Hu-Tang; Japanese name, Shosaiko-to) is a traditional
Korean, Chinese, and Japanese medicine, which has been used to treat various conditions, including hepatitis,
liver cirrhosis, and chronic and acute liver disease. SH consists of seven herbal components, of which Scutellaria
baicalensis Georgi and Zingiber officinale Roscoe, are reported to have antithrombotic and antiplatelet activities.
We investigated the antithrombotic activity of SH, including S. baicalensis and Z. officinale, as an integrative therapy.
Methods: To identify the antithrombotic activity of SH, we used a FeCl3-induced thrombus formation model.
The mechanism of SH-mediated antithrombotic activity was assessed by determining platelet aggregation and
coagulation times ex vivo, washed platelet aggregation, serotonin secretion, and thromboxane B2 formation.
Results: SH prolonged the occlusion time of thrombus formation when applied in a FeCl3-induced thrombus
formation model. SH also inhibited collagen-induced platelet aggregation ex vivo in a concentration-dependent
manner; however, it did not affect coagulation. Hence, to identify the antiplatelet effect of SH, we investigated
washed platelet aggregations in vitro. SH significantly inhibited various agonist-induced platelet aggregations,
and it completely inhibited serotonin secretion and thromboxane B2 formation.
Conclusions: The findings suggest that SH inhibited FeCl3-induced thrombus formation through antiplatelet
activity, including inhibition of platelet aggregation, and serotonin and TXB2 production. Thus, SH may be useful as
an integrative herbal formula for the treatment of thrombosis.
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Thrombus formation is a pivotal event in the pathogenesis
of cardiovascular disease. Platelets are critical in all phases
of thrombus formation, including the initial steps of ath-
erosclerosis, progression of fatty streaks to atherosclerotic
lesions, and any resulting thrombotic complications [1].
Presently, thrombotic disease is clinically treated by the ad-
ministration of acetylsalicylic acid (aspirin), adenosine di-
phosphate (ADP) receptor blockers, and glycoprotein (GP)
IIb/IIIa antagonists as directed to prevent cardiovascular
disease [2]; however, they can have systemic hemorrhagic
side effects [3]. Thrombus formation is also directly con-
nected to the initiation of coagulation in fibrin production.
Blood coagulation factor VIIa (FVIIa) is important in tissue* Correspondence: wkcho@kiom.re.kr; jyma@kiom.re.kr
†Equal contributors
Korean Medicine (KM)-Based Herbal Drug Research Group, Korea Institute of
Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 305-811,
Republic of Korea
© 2013 Lee et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfactor complex formation [4]. Following tissue injury,
membrane-bound tissue factor (TF) crucially binds to
FVIIa and the binary FVIIa/TF complex (the extrinsic
pathway), then generates FIXa (the intrinsic pathway) and
FXa, which result in formation of the Xnase complex
[5-7]. The Xnase complex, along with FVIIa/TF, converts
FX to activated factor X, which assembles with activated
factor V to form the prothrombinase complex that is di-
rectly responsible for the formation of thrombin [7].
In the atherosclerotic artery, platelets are activated to re-
spond to injury by plaque rupture or erosion, which leads
to the release of additional agonists, such as thromboxane
(TX) A2, 5-hydroxytryptamine (serotonin), and ADP, which
lead to further recruitment of platelets to injury sites
[8-10]. TXA2 has several effects as it is the major contribu-
tor of platelet aggregation via collagen, which is the most
atherogenic activator of the vessel wall [11]. Meanwhile,
serotonin is released from dense granules during platelet. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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play a role in platelet formation, and was related to the
constriction and dilation of vascular vessels [12].
Soshiho-tang (SH) is a traditional Korean, Chinese, and
Japanese medicine, and has been used to treat various con-
ditions, including hepatitis, liver cirrhosis, and chronic and
acute liver disease [13,14]. Recent studies show that SH
has various pharmacological properties, including immu-
nomodulatory effects [15], modulation of liver fibrosis [16],
and treatment of anti-interstitial pneumonia [13,14]. How-
ever, the integrative effect of SH on antithrombotic and
antiplatelet activity have not reported with regard to its
seven herbal components, including Bupleurum falcatum
Linne, Glycyrrhiza uralensis Fischer, Panax ginseng C.A.
Meyer, Pinellia ternata Breitenbath, Scutellaria baicalensis
Georgi, Zingiber officinale Roscoe, and Zizyphus jujuba
Miller var. inermis Rehder. Among these components,
S. baicalensis and Z. officinale have been reported to have
antithrombotic and antiplatelet activity [17-19]. Hence, in
this study, we investigated the antithrombotic activity
through the antiplatelet effects of SH including the use of
S. baicalensis and Z. officinale as integrative therapies.
Methods
Indomethacin, bovine serum albumin (BSA), ethylene
glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid
(EGTA), serotonin creatinine sulfate, o-phthalaldehyde
(OPT), imipramine, acetylsalicylic acid (ASA, aspirin),
and dimethyl sulfoxide (DMSO) were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). Collagen,
arachidonic acid (AA), ADP, and thrombin were pur-
chased from Chrono-Log Co. (Havertown, PA, USA).
Cephalin, thromboplastin, and bovine thrombin were
purchased from Instrumentation Laboratory Co. (Milano,
Italy). Other chemicals were of analytical grade.
Animals
Male Sprague–Dawley rats (250–300 g) and New Zealand
white rabbits (2.5-3 kg) were purchased from Sam-Tako
Animal Co. (Osan, Korea) and acclimated for 1 week at a
temperature of 24 ± 1°C and humidity of 55 ± 5%. The ani-
mals had free access to a commercial pellet diet obtained
from Samyang Co. (Wonju, Korea) and drinking water.
The animal studies have been carried out in accordance
with the Korea Institute of Oriental Medicine Care Com-
mittee Guidelines, and were approved by the Korea Insti-
tute of Oriental Medicine Care and Use Committee
(Protocol # 12–056). The animals were cared for in ac-
cordance with the dictates of the National Animal Welfare
Law of Korea.
Preparation of Soshiho-tang extract
Bupleurum Root, Glycyrrhizae Radix et Rhizoma, Gin-
seng Radix, Pinellia Tuber, Scutellaria Root, ZingiberisRhizoma Crudus, and Zizyphi Fructus were purchased
from Yeongcheon traditional herbal market (Yeongcheon,
Korea). All voucher specimens were deposited in the
herbal bank of the KM-Based Herbal Drug Research
Group, Korea Institute of Oriental Medicine.
SH was prepared according to previously reported
methods [16]. Briefly, 1674.5 g of medicinal herbal drug,
including Bupleurum Root 600 g, Glycyrrhizae Radix et
Rhizoma 100 g, Ginseng Radix 200 g, Pinellia Tuber 200 g,
Scutellaria Root 400 g, Zingiberis Rhizoma Crudus
74.5 g, and Zizyphi Fructus 100 g, was decocted with
16.745 L of boiling water in a stainless oven for 3 h
at 115°C using a Gyeongseo Extractor Cosmos-600
(Incheon, Korea), after which the decoction was fil-
tered using standard testing sieves (150 μm; Retsch,
Haan, Germany). The filtrate was lyophilized and stored
in desiccators at 4°C. The freeze-dried extract powder
was then dissolved in 50% DMSO (v/v with phosphate-
buffered saline) and filtered (pore size, 0.2 μm), then
kept at 4°C for use.
Arterial thrombus formation in vivo
Male Sprague–Dawley rats (n = 7) were orally adminis-
tered with SH (300 and 600 mg/kg) or ASA (100 mg/
kg), a positive control, for 5 days, and then anaesthetized
by intraperitoneal injection of pentobarbital (50 mg/kg).
Arterial thrombus formation in vivo was investigated as
previously described [20]. Briefly, a segment of the right
carotid artery was isolated and dissected free of the
vagus nerve and surrounding tissues. Aortic blood flow
was measured with a Blood FlowMeter (ADInstruments,
Colorado Springs, CO, USA). Arterial thrombus forma-
tion was induced by wrapping a 2-mm2 Whatman Grade
1 filter paper, saturated with 50% ferric chloride (FeCl3;
w/v, in distilled water), on the carotid artery near the
probe for 10 min. The time needed for occlusion to
occur was measured for up to 60 min, and occlusion
time was assigned a value of 60 min for vessels that did
not occlude within that time.
Platelet aggregation and coagulation times ex vivo
Ex vivo platelet aggregation was investigated as previously
described [20]. In brief, male Sprague–Dawley rats (n = 8)
were orally administered with SH (300 and 600 mg/kg)
and ASA (100 mg/kg) for 5 days, and blood was collected
60 min after the last administration. Platelet-rich plasma
(PRP) was obtained by centrifuging the blood sample at
180 × g for 10 min, and platelet-poor plasma (PPP) was
obtained by centrifuging the PRP at 2100 × g for 10 min
continuously. PRP was adjusted to 4 × 108 platelets/ml
with PPP. Platelet aggregation was measured with an
aggregometer (Chrono-Log Co.), and collagen (3 μg/ml)
and ADP (5 μM) were used as aggregation stimulators.
The plasma-activated partial thromboplastin time (APTT)
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with an Automated Coagulation Laboratory 100 Instru-
ment (Instrumentation Laboratory) as previously described
[20]. In brief, PPP was incubated at 37°C for 7 min, and
then 100 μl incubated plasma was mixed with 50 μl cephalin
in the process plate. Coagulation was triggered by the
addition of CaCl2 plus either 100 μl thromboplastin or
100 μl polibrene for the APTTand PT assays, respectively.
Washed rabbit platelet preparation and platelet
aggregation in vitro
Blood was withdrawn from the ear artery of male New
Zealand white rabbits and collected into 0.15 (v/v) ofFigure 1 Effects of SH on thrombus formation in vivo. (A) Control, (B) S
(E) bar graph is expressed from a representative data of eight individuals. A
0 mg/kg.anticoagulant citrate dextrose (ACD) solution that
contained 0.8% citric acid, 2.2% trisodium citrate, and 2%
dextrose (w/v). Washed platelets were prepared as previ-
ously described [20]. Briefly, PRP was obtained by centrifu-
gation of rabbit blood at 230 × g for 10 min. Platelets were
sedimented by centrifugation of the PRP at 800 × g for 15
min and washed with HEPES buffer (137 mM NaCl, 2.7
mM KCl, 1 mM MgCl2, 5.6 mM glucose, and 3.8 mM
HEPES, pH 6.5) containing 0.35% BSA and 0.4 mM EGTA.
The washed platelets were suspended in HEPES buffer (pH
7.4) and adjusted to 4 × 108 cells/ml. Platelet aggregation
was measured with an aggregometer (Chrono-Log Co.)
according to Born’s turbidimetry method [21]. Briefly,H 300 mg/kg, (C) SH 600 mg/kg, (D) ASA (aspirin) 100 mg/kg, and
rrows show the occlusion point by thrombus formation. **P < 0.01 vs.
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aggregometer with stirring at 1200 rpm, and then various
concentrations of SH were added. After 3 min preincu-
bation, platelet aggregation was induced by the addition of
collagen (3 μg/ml), AA (100 μM), or thrombin (0.05 U/ml).
Cell viability
Cell viability of platelets was determined as previously
described [22]. Cell death of platelets by SH treatment
was detection using a Cell Counting Kit-8 according to
the manufacturer’s instructions (Wako, Osaka, Japan). In
vitro viability was determined by measuring reduced
formazan, a colorimetric assay based on the reduction of
tetrazolium salt by cellular NADH or NADPH. The
working solution (10 μl) containing WST-1 and SH was
added to the PRP (200 μl) containing 4 × 108 platelets/
ml in a 96-well microtiter plate (Disposable Products,
Adelaide, South Australia). The absorbance of the col-
ored product (formazan dye) was read on a microplate
reader (Well Reader SK601; Seikagaku, Tokyo, Japan)
using a test wavelength of 450 nm against a reference
wavelength of 650 nm.
Serotonin secretion
Serotonin release was measured as previously described
[20]. In brief, to prevent the reuptake of secreted sero-
tonin, imipramine (a serotonin reuptake inhibitor, 5 μM)
was added to PRP. Washed rabbit platelets were treated
with various concentrations of SH at 37°C for 3 min
prior to the addition of an agonist (collagen 3 μg/ml, AA
100 μM, or thrombin 0.05 U/ml) for 5 min. An aliquot
(0.35 ml) of the washed rabbit platelets was mixed with
5 mM EDTA on ice and centrifuged at 12,000 × g for 2 min.Figure 2 Effects of SH on platelet aggregation and coagulation times
ADP (5 μM) (A, n = 8). In the coagulation assay, PPP was obtained by centr
(B, n = 9). **P < 0.01 vs. 0 mg/kg.The supernatant was mixed with 6 M trichloroacetic acid
(TCA) and centrifuged at 12,000 × g for 2 min. An aliquot
(0.3 ml) of the TCA supernatant was mixed with 1.2 ml of
the solution (0.5% o-phthalaldehyde in ethanol diluted
1:10 with 8 N HCl), placed in a boiling water bath for 10
min, and then cooled on ice. The excess lipids were
extracted with chloroform, and the fluorophore was mea-
sured at excitation and emission wavelengths of 360 nm
and 475 nm, respectively. Serotonin creatinine sulfate was
used as the standard solution to calculate the extent of
serotonin release.
Thromboxane B2 formation
Platelets were preincubated with SH or ASA at the indi-
cated concentrations for 3 min and then exposed to colla-
gen (3 μg/ml), AA (100 μM), or thrombin (0.05 U/ml), as
in the aggregation assay. Ethylene glycol bis(2-aminoethyl
ether) tetraacetic acid (EGTA, 2 mM) containing 0.1 M
KCl and indomethacin (5 mM) were then added to plate-
let suspension. Thromboxane B2 (TXB2) level was mea-
sured with an enzyme-linked immunosorbent assay
(ELISA) kit according to the manufacturer's instructions.
Statistical analysis
Results are expressed as means ± SEM, and were ana-
lyzed using Student’s t-test or an analysis of variance
(ANOVA). The results were considered significant when
P < 0.05.
Results
Effect of SH on thrombus formation
To investigate the effects of SH on arterial thrombus for-
mation in vivo, we used a rat carotid artery injury modelex vivo. Platelet aggregation was induced by collagen (3 μg/ml) or
ifuging PRP, after which APTT and PT were measured as described
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vessels of the control group were occluded within 21.8 ±
1.0 min. After oral SH treatment for 5 days, the time to
form an occlusion was significantly longer, 25.5 ± 6.2 min
and 25.9 ± 5.8 min at 300 mg/kg and 600 mg/kg of SH,
respectively. As a positive control, ASA treatment for
5 days also prolonged occlusion time to 26.8 ± 5.4 min at
100 mg/kg (Figure 1). Taken together, SH showed an
equivalent effect to ASA, although SH treatment was at
higher doses than ASA.
Effect of SH on aggregation and coagulation times ex vivo
Figure 2A shows how SH inhibited collagen-induced aggre-
gation in a concentration-dependent manner (25.3 ± 3.8%
inhibition at 300 mg/kg and 59.0 ± 8.6% at 600 mg/kg).Figure 3 Effects of SH on washed rabbit platelet aggregation and cel
aggregation by the inducer. Cell viability was measured as described. Colla
data (D, n = 4), and cell viability (E, n = 3). Data are expressed as the meanASA also inhibited collagen-induced aggregation by
66.7 ± 5.9% at 100 mg/kg. However, SH treatment did not
significantly change coagulation times, including APTT
and PT. These data indicate that SH has excellent anti-
platelet activity but does not affect coagulation.
Effect of SH on washed rabbit platelet aggregation in vitro
To confirm the antiplatelet activity of SH, we inves-
tigated the effect of SH on various agonist-induced
platelet aggregations. SH inhibited collagen- (Figure 3A),
AA- (Figure 3B), and thrombin (Figure 3C)-induced rabbit
platelet aggregations in a concentration-dependent manner
(Figure 3D). In addition, a WST-1 assay also confirmed that
the antiplatelet effect of SH was not due to cellular cytoto-
xicity (Figure 3E).l viability. Aggregation is expressed as a percentage of maximum
gen (A), AA (B), thrombin (C), expressed as a graph from representative
± S.E.M. **P < 0.01 vs. 0 μg/ml.
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Serotonin is secreted from activated platelets during plate-
let aggregation [23]. Notably, SH inhibited serotonin secre-
tion in a concentration-dependent manner, with inhibition
percentages of 17.7%, 24.1%, and 90.1% for collagen
(Figure 4A), 34.5%, 70.2%, and 91.1% for AA (Figure 4B),
and 64.6%, 88.7%, and 89.0% for thrombin (Figure 4C) at
200, 400, and 800 μg/ml, respectively. ASA, as a positive
control, potently inhibited serotonin secretion. In addition,
total serotonin content of platelets was expressed as lysis
(Figure 4).
Effect of SH on thromboxane B2 formation
In the TXB2 formation assay, SH significantly inhibited
collagen- (Figure 4D), AA- (Figure 4E), and thrombin
(Figure 4F)-induced TXB2 formation. These results indicateFigure 4 Effects of SH on serotonin secretion and TXB2 formation. Ser
and was then determined by a fluorimetric method, as a described (n = 4).
concentrations for 3 min and then exposed to (D) collagen (3 μg/ml), (E) A
mean ± SEM. **P < 0.01 vs. 0 μg/ml.that SH has an overall effect rather than a selective effect in
platelet activation. In addition, ASA, a cyclooxygenase in-
hibitor, completely suppressed the production of TXB2
from AA by cyclooxygenase-1 activation.
Discussion
In this study, we demonstrated two major findings: SH
had an antithrombotic effect via antiplatelet activity, and
the antiplatelet effect of SH involved the suppression of
serotonin secretion and TXB2 production. These results
suggests that SH may be used as an herbal formula to
manage atherosclerosis and thrombotic disease, although
it still needs further study with respect to its molecular
mechanisms.
Activation and aggregation of platelets play an im-
portant role in thrombotic complications, such asotonin secretion was induced by (A) collagen, (B) AA, or (C) thrombin
TXB2 formations were preincubated with SH or ASA at the indicated
A (100 μM), or (F) thrombin (0.05 U/ml). Data are expressed as the
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coronary syndromes [8-10]. In the clinical treatment for
thrombotic diseases, inhibition of platelet activation
leads to suppression of thrombosis formation and pro-
gression, and therefore, it is an important target for
preventing complications after an acute coronary inci-
dent [24]. Generally, platelet aggregation and activation
are mainly mediated through adhesion of platelets to
the site of injury, and through the action of endogenous
agonists such as collagen, ADP, and thrombin, followed
by the release of TXA2 and serotonin, which act as
amplification factors in platelet aggregation [25,26].
In this study, SH significantly prolonged the occlu-
sion time of thrombus formation when applied in a
FeCl3-induced thrombus formation model. Our results
show that SH, at a concentration of up to 300 mg/kg,
had an equivalent effect to ASA, although SH was ad-
ministered at a higher dose than ASA (Figure 1).
SH inhibited collagen-induced platelet aggregation
ex vivo (Figure 2A) in a concentration-dependent man-
ner without affecting coagulation, including APTT and
PT (Figure 2B), indicating that SH inhibits thrombus
formation by antiplatelet activity rather than anticoagu-
lant activity.
Accordingly, we investigated the effect of SH on vari-
ous agonist-induced platelet aggregations to identify the
antiplatelet activity. SH potently inhibited collagen-,
AA-, and thrombin-induced platelet aggregation in a
concentration-dependent manner (Figure 3) without
cellular cytotoxicity (Figure 3E). In platelet activation,
serotonin secretion is the indicator to identify the levels
of platelet activation because serotonin is released from
activated platelets during platelet aggregation [23]. SH
significantly inhibited collagen-, AA-, and thrombin-
induced serotonin secretion as well as agonist-induced
TXB2 formation (Figure 4). TXA2, as the active form of
TXB2, is the major contributor to platelet aggregation
and activation [11]. Inhibition of serotonin and throm-
boxane B2 production in our results indicate that inhi-
bition of platelets by SH may be an overall effect rather
than a selective effect of platelet activation.
Additionally, the protective effects of S. baicalensis
and Z. officinale, which are components of SH, have
been reported in cardiovascular disease [17-19]. In a
previous report, S. baicalensis prolonged thrombus for-
mation by 23.79% due to its antithrombotic activity,
and inhibited platelet aggregation by 45.52% due to its
antiplatelet activity [17]. Also, Z. officinale a bioactive
ginger, reportedly could have antiplatelet activity [18].
In comparison to previous results on the individual
components of SH, our study suggests that SH has a
complementary effect whereby all of the components
work together to create an improved antithrombotic
effect.Conclusions
Taken together, this study suggests that SH, which con-
tains S. baicalensis and Z. officinale, inhibited thrombus
formation through antiplatelet activity, resulting in the
inhibition of platelet aggregation and suppression of
serotonin and TXB2 production.
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